journal article·2026-07

Lipid Droplet‐Powered Microneedles Orchestrate Tumor Microenvironment Remodeling to Enhance Immune Activation in Melanoma

Somayeh Mahdinloo, Ping‐An Zhang, Qiuyu Zhang, Mulan Deng, Tianfeng Lan, Na Tao, Jiaxuan Li, Luyao Wang, Yan Guo, Haoming Liu, Xing‐Jie Liang, Jiang Ouyang

Advanced Functional Materials· Volume 36· Issue 56
Publisher page

Abstract

ABSTRACT Melanoma progression is sustained by profound metabolic rewiring and immune suppression within the tumor microenvironment, where adipocyte‐derived lipid droplets (LDs) serve as key metabolic regulators. Here, we exploit this intrinsic biology by engineering resveratrol‐loaded LDs (RSV‐LDs) as natural, lipophilic nanocarriers to drive intracellular delivery and immunometabolic reprogramming. To achieve precise and localized administration, RSV‐LDs were integrated into soluble microneedles, enabling efficient transdermal delivery while minimizing systemic exposure. This strategy markedly increased the M1/M2 macrophage ratio and promoted robust CD8 + T‐cell infiltration, reshaping the immunosuppressive tumor niche. To further potentiate the activity of these infiltrating CD8 + T‐cells, we incorporated ROS‐responsive anti‐PD1 nanoparticles (aPD1‐NPs) via a thioketal linker, enabling tumor‐specific antibody release within the oxidative tumor milieu. Notably, transcriptomic and single‐cell analyses revealed coordinated activation of innate immune and metabolic pathways following treatment, with TLR7/8‐expressing monocytes emerging as a central communication hub among T, NK, and B cell populations. Together, these findings demonstrate that the microneedle‐based RSV‐LD/aPD1 platform induces localized metabolic and immune reprogramming, reshaping the tumor microenvironment to enhance antitumor immunity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid metabolism and biosynthesis · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Guangzhou Institute of Cancer Research, the Afiliated Cancer Hospital & School of Biomedical Engineering Guangzhou Medical University Guangzhou China

National Clinical Research Center for Respiratory Disease The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

College of Science Changsha Institute of Technology Changsha Hunan China

Funding

National Natural Science Foundation of China

References (53)

Show source-provided references
1. 10.1038/s41467‐023‐38831‐910.1038/s41467‐023‐38831‐9 ↗
2. 10.1002/adma.20210062910.1002/adma.202100629 ↗
3. 10.1016/j.cmet.2014.06.01110.1016/j.cmet.2014.06.011 ↗
4. 10.1002/pros.2347910.1002/pros.23479 ↗
5. 10.1002/adma.20252107810.1002/adma.202521078 ↗
6. 10.1007/s12020‐016‐1212‐210.1007/s12020‐016‐1212‐2 ↗
7. 10.3390/molecules2922535910.3390/molecules29225359 ↗
8. 10.1186/s12882‐016‐0233‐710.1186/s12882‐016‐0233‐7 ↗
9. 10.18632/aging.10264610.18632/aging.102646 ↗
10. 10.1111/j.1749‐6632.2010.05842.x10.1111/j.1749‐6632.2010.05842.x ↗
11. 10.1038/s41698-024-00522-z10.1038/s41698-024-00522-z ↗
12. 10.1186/s13045‐023‐01498‐210.1186/s13045‐023‐01498‐2 ↗
13. 10.1038/s41568‐024‐00743‐110.1038/s41568‐024‐00743‐1 ↗
14. 10.1038/s41467-019-11911-510.1038/s41467-019-11911-5 ↗
15. 10.1186/s12951‐024‐02622‐110.1186/s12951‐024‐02622‐1 ↗
16. 10.3390/polym1404068710.3390/polym14040687 ↗
17. 10.1016/j.matt.2019.08.00710.1016/j.matt.2019.08.007 ↗
18. 10.2119/molmed.2011.0016310.2119/molmed.2011.00163 ↗
19. 10.1016/j.bbabio.2016.03.00910.1016/j.bbabio.2016.03.009 ↗
20. 10.1186/s11671‐018‐2728‐610.1186/s11671‐018‐2728‐6 ↗
21. 10.1002/smll.20210511810.1002/smll.202105118 ↗
22. 10.1002/anie.20171202710.1002/anie.201712027 ↗
23. 10.1016/j.carbpol.2017.09.09510.1016/j.carbpol.2017.09.095 ↗
24. Tumor Microenvironment‐responsive Fenton Nanocatalysts for Intensified Anticancer Treatment
25. 10.1016/j.colsurfb.2020.11122310.1016/j.colsurfb.2020.111223 ↗
26. 10.1016/j.ejpb.2025.11468710.1016/j.ejpb.2025.114687 ↗
27. 10.3109/1071754100366779810.3109/10717541003667798 ↗
28. 10.1038/nrc338010.1038/nrc3380 ↗
29. 10.1146/annurev‐immunol‐032712‐10000810.1146/annurev‐immunol‐032712‐100008 ↗
30. 10.1038/s42003‐024‐06930‐y10.1038/s42003‐024‐06930‐y ↗
31. 10.1186/s43556‐025‐00305‐310.1186/s43556‐025‐00305‐3 ↗
32. 10.1016/j.cellimm.2016.11.00210.1016/j.cellimm.2016.11.002 ↗
33. 10.4049/jimmunol.150014610.4049/jimmunol.1500146 ↗
34. 10.1016/j.redox.2016.09.00510.1016/j.redox.2016.09.005 ↗
35. Interleukin‐10 Exhibit Dose‐dependent Effects on Macrophage Phenotypes and Cardiac Remodeling after Myocardial Infarction
36. 10.1016/j.apmt.2021.10111010.1016/j.apmt.2021.101110 ↗
37. 10.1016/j.jconrel.2025.01.05110.1016/j.jconrel.2025.01.051 ↗
38. 10.1016/j.mattod.2026.10323010.1016/j.mattod.2026.103230 ↗
39. 10.1186/s12951-023-01815-410.1186/s12951-023-01815-4 ↗
40. 10.1038/s41598-018-19463-210.1038/s41598-018-19463-2 ↗
41. Resveratrol‐driven Macrophage Polarization: Unveiling Mechanisms and Therapeutic Potential
42. 10.3390/molecules2518428210.3390/molecules25184282 ↗
43. 10.1002/adma.20250813710.1002/adma.202508137 ↗
44. 10.1021/jacs.6c0154210.1021/jacs.6c01542 ↗
45. 10.1186/s40425‐015‐0067‐z10.1186/s40425‐015‐0067‐z ↗
46. 10.1016/j.mtbio.2025.10162610.1016/j.mtbio.2025.101626 ↗
47. 10.2147/IJN.S50553910.2147/IJN.S505539 ↗
48. Functional and Clinical Characteristics of Cell Adhesion Molecule CADM1 in Cancer
49. 10.1186/s13046‐024‐03218‐110.1186/s13046‐024‐03218‐1 ↗
50. Targeting Toll‐Like Receptor 7/8 for Immunotherapy: Recent Advances and Prospectives
51. 10.1021/acs.biomac.0c0081210.1021/acs.biomac.0c00812 ↗
52. 10.1016/j.biomaterials.2018.02.03410.1016/j.biomaterials.2018.02.034 ↗
53. 10.1021/acs.nanolett.9b0058410.1021/acs.nanolett.9b00584 ↗